ReviewCurrent cardiology reports2020
Heart Failure with Preserved Ejection Fraction-a Concise Review.
Review in Current cardiology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Diagnosis of heart failure with preserved ejection fraction: a systematic narrative review of the evidence.Heart failure reviews · 2024Pooled it
- Gut Microbiota in Heart Failure with Preserved Ejection Fraction: Clinical Phenotyping and Therapeutic Opportunities.Biomedicines · 2026Article
- Noncoding and coding mechanisms of aging-related heart failure with preserved ejection fraction associated with thyroid dysfunction.Disease models & mechanisms · 2025Article
- Dysregulated ProteinCirculation research · 2025Article
- Association of Long-Term Body Mass Index Variability With the Development of Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction Across Patterns of Weight Change.Journal of the American Heart Association · 2025Article
- The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF).Cardiovascular diabetology · 2025Review
- The Impact of Continuous Cardiac Rehabilitation on the Psychological and Physiological Prognosis of Patients with Heart Failure-A Retrospective Study.Therapeutics and clinical risk management · 2025Article
- Anti-SRP Antibodies and Myocarditis in Systemic Sclerosis Overlap Syndrome with Immune-Mediated Necrotizing Myositis (IMNM).Medicina (Kaunas, Lithuania) · 2024Review
- Heart Failure with Preserved Ejection Fraction: The Pathophysiological Mechanisms behind the Clinical Phenotypes and the Therapeutic Approach.International journal of molecular sciences · 2024Review
- Insights into the Interaction of Heart Failure with Preserved Ejection Fraction and Sleep-Disordered Breathing.Biomedicines · 2023Review
- Phenomics and Robust Multiomics Data for Cardiovascular Disease Subtyping.Arteriosclerosis, thrombosis, and vascular biology · 2023Review
- Heart Failure with Preserved Ejection Fraction: Pathogenesis, Diagnosis, Exercise, and Medical Therapies.Journal of cardiovascular translational research · 2023Review
- Vascular compliance and left ventricular compliance cross talk: Implications for using long-term heat acclimation in cardiac care.Frontiers in physiology · 2023Review
- Genome Editing and Heart Failure.Advances in experimental medicine and biology · 2023Article
- Defining the Phenotypes for Heart Failure With Preserved Ejection Fraction.Current heart failure reports · 2022Review
- Heart Failure with Preserved Ejection Fraction and Obstructive Sleep Apnea: A Novel Paradigm for Additional Cardiovascular Benefit of SGLT2 Inhibitors in Subjects With or Without Type 2 Diabetes.Advances in therapy · 2022Article
- Empagliflozin Preserves Skeletal Muscle Function in a HFpEF Rat Model.International journal of molecular sciences · 2022Article
- Review
- Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction.BMC cardiovascular disorders · 2022Article
- Targeting MuRF1 by small molecules in a HFpEF rat model improves myocardial diastolic function and skeletal muscle contractility.Journal of cachexia, sarcopenia and muscle · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewHeart failure with preserved ejection fraction (HFpEF) is a relatively new disease entity used in medical terminology; however, both the number of patients and its clinical significance are growing. HFpEF used to be seen as a mild condition; however, the symptoms and quality of life of the patients are comparable to those with reduced ejection fraction. The disease is much more complex than previously thought. In this article, information surrounding the etiology, diagnosis, prognosis, and possible therapeutic options of HFpEF are reviewed and summarized. RECENT
findingsIt has recently been proposed that heart failure (HF) is rather a heterogeneous syndrome with a spectrum of overlapping and distinct characteristics. HFpEF itself can be distilled into different phenotypes based on the underlying biology. The etiological factors of HFpEF are unclear; however, systemic low-grade inflammation and microvascular damage as a consequence of comorbidities associated with endothelial dysfunction, oxidative stress, myocardial remodeling, and fibrosis are considered to play a crucial role in the pathogenesis of a disease. The H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.